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Background  There are not many studies about treatment of shoulder spasticity. Although botulinum toxin injection has 
been reported to be effective for shoulder spasticity, the effectiveness was judged by pain and limited motion change, 
but not the spasticity itself. Shoulder spasticity is considered to play an important role in hemiplegic frozen shoulder. 
However, the subscapularis muscle, unlike the pectoralis major muscle, is located deep beneath scapula, where 
conventional injection is difficult to perform. As extracorporeal shock wave therapy (ESWT) has been reported to be 
effective for spasticity relief, and we thought spasticity of subscapularis muscle located deep beneath the scapula would 
be a good candidate for ESWT treatment. This study was to evaluate the beneficial effects of radial ESWT (rESWT) on 
spastic subscapularis muscle in stroke patients.
Methods  This is an uncontrolled, prospective, unicenter, clinical pilot study. Stroke patients (n=57; mean age 55.4 
years) with spastic shoulders were recruited between June 2011 and February 2012 at the University Rehabilitation 
Hospital. rESWT was administered to each patient every two or three days for two weeks (five total treatments). 
Evaluation consisted of 11 measurements for each patient; at the start of each of the five treatments and once per week 
during the following six weeks. Spasticity was measured at external rotator muscles of the shoulder using the modified 
Ashworth scale (MAS), and passive range of motion (ROM) of the shoulder in external rotation was recorded. Pain 
was measured using a visual analogue scale (VAS) during passive ROM of the shoulder in external rotation, and was 
additionally recorded for patients who preserved cognitive and communicative ability (Pain group).
Results  Reduction in MAS and VAS and improvement of ROM during and after rESWT treatments were prominent 
compared to baseline. The reduction in MAS and VAS and improvement of ROM continued four weeks after the last 
treatment and the effects of the treatment decreased afterward.
Conclusion  rESWT will be able to provide stroke patients with an effective and safe procedure for the reduction of 
spasticity and pain as well as for the improvement of ROM of spastic shoulders.
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Spasticity is defined as a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks 
due to hyperexcitability of the stretch reflex.1 The sustained 
contraction of a group of spastic muscles may result in 
permanent contracture and skeletal deformities.2
Specific treatments for spastic shoulder muscles are 
still a topic of research interest. Muscles involved with 
internal rotation of the shoulder, the subscapularis and 
the pectoralis major, play a pivotal role in the painful, 
contracted shoulder.3 Although spasticity treatment for the 
subscapularis muscle is more effective to increase the range 
of motion of the spastic shoulder compared to treatment of 
the pectoralis muscle,4 the muscles that should be targeted 
for a more effective treatment have not been studied. 
Studies of botulinum toxin injections into the internal 
rotator of the spastic shoulder reported that individual 
injections into the pectoralis major5-7 or the subscapularis8 
decreased pain severity but had little effect on spasticity. 
It would be ideal to treat both the pectoralis major and 
subscapularis muscles to decrease spasticity in the 
shoulder. However, the subscapularis is located too deep 
inside the scapula to treat accurately and safely, while the 
pectoralis major is superficial. The efficacy of botulinum 
toxin is maximized by injecting the toxin close to the 
site of action (motor endplates),9 and the deep location 
of the subscapularis makes this injection difficult. Most 
studies failed to confirm that botulinum toxin injection 
into the subscapularis was appropriately placed at the site 
of action. With regard to the upper and lower subscapular 
nerve block, accuracy and safety are similar to that of the 
intramuscular botulinum toxin injection. Furthermore, 
most research on botulinum toxin injection into spastic 
shoulders has focused on shoulder pain, not spasticity, as 
the main outcome.5-8,10 Such research should recruit patients 
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with enough cognition to score the pain severity; but the 
sample size of these studies were small. This would be a 
limitation when evaluating the efficacy of these treatments 
on spasticity.
Extracorporeal shock wave therapy (ESWT) has been 
suggested as a non-invasive, alternative treatment for 
spasticity. ESWT involves a sequence of single sonic 
pulses characterized by high peak pressure (100 MPa), fast 
pressure rise (<10 ns), and short duration (10 μs). ESWT 
is conveyed by an appropriate generator to a specific target 
area with an energy flux density in the range of 0.003 to 
0.890 mJ/mm2. The waves of radial extracorporeal shock 
wave therapy (rESWT), compared with that of conventional 
focused ESWT, disperse eccentrically from the applicator 
tip without concentrating the shock wave field in the 
targeted tissue.11 The therapeutic effect of rESWT occurs 
a few centimeters deep within the skin surface (0 to 3.5 
cm).12,13 Some studies have demonstrated a reduction in 
spasticity after applying ESWT (including rESWT) without 
significant side effects.12,14-16
Because injection of botulinum toxin into the subscapularis 
at the motor endplate is technically difficult, our study 
focused on assessing the beneficial effects of rESWT on 
the spastic subscapularis muscle but not on the pectoralis 
muscles in stroke patients. In this study, the effectiveness 
of treatment was evaluated by observing spasticity itself 
rather than functional measurements. We hypothesized 
that rESWT would be effective and safe for the reduction 
of spasticity of the shoulder in external rotation because it 
would successfully treat the spastic subscapularis.
METHODS
Subjects
Patients were recruited for this study from among 
hospitalized patients at a university hospital between June 
2011 and February 2012. The inclusion criteria included: 
(1) duration of stroke ≥9 months; (2) hemiplegia or 
quadriplegia (in cases of quadriplegia, the more affected 
shoulder with respect to spasticity and limitation of range 
of motion (ROM)); (3) limitation of passive external 
rotation of the spastic shoulder ≥20°; and (4) modified 
Ashworth scale (MAS) ≥1. For pain assessment, patients 
who preserved cognitive and communicative ability, all 
subjects who scored above 24 on the Mini-Mental Status 
Examination,17 and whose visual analogue scale (VAS) for 
shoulder pain was more than 4/10 were included (Group 
II). The exclusion criteria included: (1) intra-articular 
injection into the affected shoulder during the previous 
six months or use of systemic corticosteroids during the 
previous four months; (2) presence of another explanation 
for the pain (e.g. fracture, complex regional pain syndrome, 
or radiculopathy); (3) prior surgery to either the affected 
shoulder or neck region; (4) presence of an unstable 
medical condition or uncontrolled systemic disease; 
(5) prior treatment with botulinum toxin in the affected 
shoulder within nine months; and (6) prior treatment with 
ESWT to the shoulder. Approval from the Institutional 
Review Board was obtained before conducting the study. 
Written informed consent was obtained from all participants 
or main care givers after an explanation about the nature of 
the study and examination.
rESWT
Masterplus MP200® (Storz Medical AG, Tagerwillen, 
Switzerland) was as the rESWT machine used and was 
provided by a physiatrist. The treatment was administered 
every two or three days for two weeks (five times total) 
according to the manufacturer’s recommendations. 
The patient was positioned lying on their side with the 
affected side up. The shoulder was placed in flexion, 
with external rotation and abduction to facilitate access 
to the subscapularis muscle with the probe (Figure 1). In 
this position, we found that only the teres major muscle 
is located above the subscapularis and the pectoralis 
major is not placed in the treatment window.18 The skin 
overlying the tip of the acromion and the inferior angle of 
the scapula was marked with a pen. The target area for the 
subscapularis was medial to the midpoint between the tip 
of the acromion and the inferior angle of the scapula. The 
target area for rESWT was arbitrary because no guideline 
has been established. The frequency applied was 8 Hz. 
There were 3000 pulses per session with an energy flux 
density 0.63 mJ/mm2 (1.6 bar). Deep impact (diameter 15 
mm) with the depth of 0–60 mm was used for the head of 
the rESWT machine. One session took about 15 minutes. 
During the study period, all patients were allowed to take 
previously prescribed oral anti-spastic medications and/or 
analgesics and received a standard course of physiotherapy 
including ROM exercise, massage, passive stretching, 
and physiotherapy with active movement. However, 
no additional analgesics or anti-spastic medications for 
shoulder conditions were permitted.
This pilot study was a non-controlled, prospective, clinical 
trial. The patients were examined by another physiatrist 
who was not blinded to the study. The primary outcome 
measures were spasticity during the external rotation of 
the shoulder using the MAS while in a seated position. 
For convenience of statistical analysis, MAS grade 1+ 
was matched to point 2; grades 2, 3 and 4 were matched to 
Figure 1. Patient’s position for treatment. A: during the rESWT 
procedure, the patient was lying on their lateral side with the 
treatment side up. The shoulder was placed in a position of 
flexion, external rotation, and abduction so the rESWT probe 
was able to access the posterior axillary fold. B: in this position, 
only the teres major muscle is located above the subscapularis 
and the pectoralis major is not placed in the treatment window 
(circle). rESWT: radial extracorporeal shock wave therapy. P: 
pectoralis major.
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points 3, 4 and 5.19 Secondary outcome measures were the 
passive ROM of the shoulder for external rotation using 
goniometry while in a seated position and VAS only in the 
Group II. In Group II, pain was measured using a VAS on 
a scale of 0–10 during passive ROM of the shoulder in 
external rotation. Adverse events and rESWT-related pain 
were monitored throughout. Evaluation consisted of 11 
measurements for each patient: at the start of each treatment 
(five times) and once per week in the following six weeks 
(six times).
Sample size was determined a priori, assuming a paired 
t test with α equal to 0.05 and power at 80% and the 
Bonferroni correction. The sample size was calculated 
based on ability to detect differences (δ) of 1.1 on the 
MAS at 1-week follow-up (primary outcome measure), 
with standard deviations of 1.2 calculated from results of 
a recent article using the Lehr’s formula (16/(2×δ/σ)) and 
a 20% drop-out rate.10,16,20 According to these calculations, 
more than 57 subjects were needed.
A linear mixed model was used to evaluate changes in 
range of motion, MAS, and visual analogue scale over 
time. Time was considered a categorical value. The fixed 
time effect model was used. A possible difference in 
sequence across the baseline to 6-week follow-up was 
analyzed. The multiple comparisons with the Bonferroni 
correction as the post-hoc analysis were used to compare 
any point of the rate change that was significantly different 
from baseline. Time was considered a continuous value. 
The estimates of change in the slope between the baseline 
and 4-week follow-up and the 4-week to 6-week follow-up 
were analyzed. Time by indicator variable (before and after 
the 4-week follow-up interaction) was considered a fixed 
effect. The data were presented as the mean ± standard 
deviation (SD) and 95% confidence intervals (95% CI). 
Statistical calculations and analyses were performed with 
SAS version 9.1.3 (SAS Institute Inc., USA), and null 
hypotheses of no difference were rejected if P-values were 
less than 0.05.
RESULTS
Overall, 57 patients with a mean age of 55.4 years (range, 
20–70 years) were enrolled. General characteristics of the 
patients are shown in the Table 1. All but two patients in 
the study were receiving anti-spastic medication. None of 
the patients were lost to follow-up. No serious side effects 
were observed over the 6-week follow-up period. Post-
treatment pain rated <4 on VAS was reported by seven 
patients in Group II, and one patient experienced petechiae 
that disappeared spontaneously.
Table 2 shows the passive ROM and MAS of the shoulder 
in external rotation and VAS (only in Group II) at baseline 
and at specific time points. Figure 2 shows the mean 
profile graphs of these same parameters. Post-hoc analysis 
revealed that the reduction of MAS and VAS, and the 
improvement of ROM during and after rESWT were 
significantly different than those same measurements at 
baseline (Table 3). Table 4 shows the changes of the slope 
and interaction before and after the 4-week follow-up, the 
time point at which the values changed significantly. All 
parameters showed a time effect. The reduction of MAS 
and VAS, and the improvement in ROM continued four 
weeks after treatment. However, the effects of the treatment 
decreased after four weeks. 
DISCUSSION
This study demonstrates that rESWT treatment of the 
spastic subscapularis reduced spasticity and pain, and 
improved the ROM of the shoulder after five sessions 
of rESWT. The greatest amount of improvement in the 
measured parameters occurred at week four, but by week 
six the improvement was decreasing.
Although the effect of ESWT on the spastic shoulder 
has not been reported, Vidal et al14 reported a significant 
decrease in the Ashworth Scale and an increase in the ROM 
of the upper or lower extremities in 40 spastic muscles of 
spastic cerebral palsy patients treated with rESWT and that 
these improvements were maintained for ≥8 weeks after 
treatment. Manganotti and Amelio16 reported that after 
active ESWT, a significant decrease in muscle tonicity was 
noted on wrist and finger flexor muscles in all patients with 
Table 1. Patient characteristics
Items Total (n=57) Group II (n=18)
Patient characteristics
  Age (years, mean±SD) 55.4±13.2 53.4±16.8
  Gender (female, (n (%)) 24 (42.1) 7 (38.9)
Past medical history (n (%))
  Ischemic stroke 22 (38.6) 7 (38.9)
  Hemorrhagic stroke 35 (61.4) 11 (61.1)
  Hemiplegia 46 (80.7) 17 (94.4)
  Quadriplegia 11 (19.3) 1 (5.6)
  Anti-spastic medication 55 (96.5) 16 (88.9)
  Analgesics 20 (35.1) 15 (83.3)
Stroke onset (month, mean±SD) 24.6±11.7 22.2±8.2
Modified Rankin scale (mean±SD) 3.8±0.8 2.8±0.4
Group II: patients who rated their shoulder pain; SD: standard deviation. 
Table 2. Outcome measures at each time point
Time Total ROM (°) Total MAS VAS (GII)
ESWT1 50.0±15.3 2.7±0.9 7.9±1.5
ESWT2 49.2±16.0 2.3±0.9 6.9±1.6
ESWT3 54.1±15.9 2.1±0.8 6.1±1.8
ESWT4 59.8±16.4 1.9±0.8 4.8±1.5
ESWT5 63.5±15.0 1.8±0.8 4.4±1.1
Week 1 67.0±14.9 1.7±0.7 3.9±1.3
Week 2 69.0±14.3 1.6±0.7 3.7±1.6
Week 3 70.6±13.1 1.5±0.6 3.5±1.6
Week 4 72.7±12.5 1.4±0.6 3.4±1.5
Week 5 63.9±14.2 1.9±0.8 3.7±1.4
Week 6 56.1±14.8 2.1±0.9 4.5±1.2
Values are estimated means± standard deviations. ROM: range of motion. MAS: 
modified Ashworth scale. VAS: visual analogue scale. ESWT: extracorporeal 
shock wave therapy. Total ROM: the passive ROM of the shoulder in external 
rotation in all patients. Total MAS: MAS during the external rotation of the 
shoulder. GII: patients who rated their shoulder pain. ESWT1: just before the 1st 
ESWT(baseline). ESWT2: just before the 2nd ESWT. Week1: one week after the 
5th ESWT.
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stroke at the 1 week and 4-week follow-ups, and that ten 
of the 20 patients showed persistent reduction in muscle 
tone 12 weeks after therapy. Furthermore, a significant 
decrease in the Ashworth Scale, an increase in the ROM, 
and an increase in the whole plantar surface area of the 
treated limb were observed in the spastic equinus foot of 
all cerebral palsy patients following a single active shock 
wave stimulation; this effect lasted for four weeks in all 
patients.15 Different ESWT modalities, radial ESWT14 vs. 
focused ESWT,15,16 and the numbers of treatment sessions, 
three sessions at intervals of one week14 vs. one session,15,16 
were used in previous studies that showed the positive 
effects of ESWT for spasticity. Our study also showed that 
the anti-spastic effects of rESWT were maintained until the 
4-week follow-up.
Previous studies on the effect of botulinum toxin for 
treating spastic shoulder emphasized the effect on pain 
more than spasticity. Since the reduction of the spasticity 
did not directly coincide with pain relief in these studies, 
the mechanisms of action for botulinum toxin’s analgesic 
effects were theorized to be acting on the neurotransmission 
afferent pathways and inhibiting substance P production.21,22 
Spasticity creates muscle shortening, which can lead to 
pain, especially when the muscles are stretched. Muscle 
shortening and pain also inhibit movement and reduce joint 
ROM. However, pain and contractures in other soft tissues 
may have contributed to the overall pain and limitation of 
motion of the shoulder. To focus on the effect on spasticity, 
severely spastic patients whose pain level could not be 
measured were included in this study. The anti-spastic 
Figure 2. The mean profile graph of the change in the passive ROM of the shoulder in external rotation over time in all patients (A). The 
mean profile graph of the change in MAS during the external rotation of the shoulder over time in all patients (B). The mean profile graph 
of the change in VAS during the passive ROM of the shoulder in external rotation over time in the patients who could rate their shoulder 
pain (C). ROM (°): Range of motion. MAS: modified Ashworth scale.VAS: visual analogue scale. GII: group II, patients who were rated 
their shoulder pain. ESWT: extracorporeal shock wave therapy. ESWT1: just before the 1st ESWT (baseline). ESWT2: just before the 2nd 
ESWT. Week 1: one week after the 5th ESWT.
Table 3. Comparison of outcome measures between baseline and each time point
Time
Total ROM Total MAS VAS (GII)
Raw Adjusted Raw Adjusted Raw Adjusted
Baseline–ESWT2 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Baseline–ESWT3 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Baseline–ESWT4 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Baseline–ESWT5 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Baseline–Week 1 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Baseline–Week 2 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Baseline–Week 3 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Baseline–Week 4 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Baseline–Week 5 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Baseline–Week 6 <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Analyzed by using a mixed model with post hoc test.*P <0.05 Raw: raw P-value. Adjust: adjusted P-value (Bonferroni correction) (multiplied by the number of 
measurements (10)). ROM: range of motion; MAS: modified Ashworth scale; VAS: visual analogue scale; ESWT: extracorporeal shock wave therapy. Total ROM: the 
passive ROM of the shoulder in external rotation in all patients; Total MAS: MAS during the external rotation of the shoulder; GII: patients who were rated their shoulder 
pain; ESWT1: just before the 1st ESWT (baseline); ESWT2: just before the 2nd ESWT; Week1: one week after the 5th ESWT.
Table 4. Comparison of outcome measures before and after the 4-week follow-up
Time
Total ROM Total MAS GII VAS
Β (95% CI) P values Β (95% CI) P values Β (95% CI) P values
Before week 4 3.804 (3.577 to 4.030) –0.150 (–0.164 to –0.136) –0.567(–0.618 to –0.515)
After week 4 –7.719 (–10.200 to –5.238) 0.263 (0.109 to 0.417) 0.778(0.211 to 1.345)
Before vs. after week 4 –11.523 (–14.014 to –9.032) <0.0001* 0.414 (0.256 to 0.568) <0.0001* 1.344(0.775 to 1.914) <0.0001*
The estimates of change in the slope between the baseline and 4-week follow-up and the 4-week to 6-week follow-up were analyzed.*P <0.05. ß: the slope. CI: confidence 
interval. ROM: range of motion. MAS: modified Ashworth scale. VAS: visual analogue scale. Total ROM: the passive ROM of the shoulder in external rotation in all 
patients. Total MAS: MAS during the external rotation of the shoulder. GII: patients who were rated their shoulder pain. Week 4: four weeks after the 5th extracorporeal 
shock wave treatment.
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effect of the rESWT on the shoulder might be clearer if 
only severely spastic shoulders were evaluated.
ESWT is a safe, non-invasive modality for treating 
spasticity.14-16 A study applying rESWT or focused ESWT 
to spastic muscles did not find side effects during a twelve 
week follow-up.16 In addition, when applied to children 
with cerebral palsy, there were no side effects.15 We did not 
observe any serious side effects in this study although some 
patients complained of post-treatment pain and one patient 
had petechiae which resolved spontaneously. However, 
since a patient reported petechiae, further evaluation of the 
long-term safety for a population taking anticoagulants or 
platelet inhibitors is needed.
The mechanisms of ESWT on spasticity due to central 
nervous system injury are still unknown. Variable 
mechanisms have been proposed, including inducing 
nitric oxide synthesis,23 decreasing spinal excitability,24 
and stimulating mechanical vibrations.24 Additionally, 
the reduction in spasticity could be caused by improving 
the stiffness of connective tissue by directly acting on the 
fibrosis of chronic hypertonic muscles.16 However, the 
effect of ESWT on spinal excitability can be excluded 
as the main mechanism because no significant changes 
occurred in F wave minimal latency, H-reflex latency, or 
H-M ratio after ESWT.12,16 In addition, because the latency 
and amplitude of the compound muscle action potential 
and the conduction velocity of the peripheral nerve were 
not changed after ESWT, the effect of ESWT on the 
peripheral nerves and a botulinum toxin A-like effect on 
neuromuscular blockage can be ruled out.
Treatment with rESWT, like botulinum toxin injections, 
may have a positive effect on pain and limited ROM of 
the shoulder in addition to a decrease in spasticity. Perhaps 
because of the effects of ESWT, localized ischemia in 
the areas of abnormal shortening of the muscles could 
improve, in turn inhibiting an increase in metabolism, 
reducing secretion of various pain inducing substances, 
inhibiting the induction of pain due to excessive stimulation 
of nociceptors of muscles, and increase the ROM of the 
shoulder.25 Further studies are needed to elucidate the 
mechanism of the effects of ESWT on spasticity.
When botulinum toxin injections are applied to the 
spastic muscles, the smallest effective dose of botulinum 
toxin should be injected as close as possible to the motor 
endplate zone to ensure maximum efficacy with minimum 
side effects. As previously mentioned, treatment of the 
subscapularis is technically difficult due to its deep location. 
In addition, to avoid the formation of antibodies, botulinum 
toxin injection should not be repeated at the same site 
within six months.26 Compared with botulinum toxins, 
ESWT has several advantages.While needle injections 
with botulinum toxins can cause tissue damage to adjacent 
structures, ESWT can be used safely on the subscapularis 
because it is not necessary to apply it exactly on the motor 
point. Repetitive or cyclic application of ESWT can also 
be considered to maintain the reduced spasticity because 
ESWT might not stimulate the formation of antibodies. In 
addition, ESWT is non-invasive and relatively inexpensive. 
However, further study is needed to determine which 
treatment has a greater anti-spastic effect.
rESWT, compared with conventional focused ESWT, is 
a low- to medium-energy shock wave generated when 
a projectile is accelerated by compressed air and hits an 
applicator.27 The waves disperse eccentrically from the 
applicator tip without concentrating the shock wave field 
in the tissue. Currently, it remains uncertain whether 
rESWT therapy is superior to focused ESWT in relieving 
spasticity. A previous study comparing the effectiveness 
of focused ESWT at different intensity levels and rESWT 
for treating plantar fasciitis suggested that rESWT was 
the best treatment, followed by low-, medium-, or high-
intensity ESWT, and that the success rates of treatment 
were not related to the energy levels of ESWT.28 rESWT 
was recommended over focused ESWT for treating plantar 
fasciitis due to its lower cost and better effectiveness in 
clinical practice.28 Focused ESWT generates rapidly-rising 
acoustic waves with high peak-pressure amplitudes, and 
the majority of energy flux is concentrated on a small 
focal point. When using ESWT therapy for the treatment 
of spasticity, it has been applied to the entire muscle belly 
rather than a small area in the muscle.15,16 Considering the 
potential advantages of rESWT, as well as the results of our 
study and the other aforementioned study,14 rESWT should 
be effective for the treatment of spasticity.
The limitations of this study include the lack of a control 
group and the short observation period. It is not possible to 
remove all effects of conventional rehabilitation without a 
control group. However, all patients in the study had strokes 
at least nine months previous and had not had a change in 
their performance in spite of their existing physical exercise 
programs or medical treatments within the month prior 
to participation. Most patients demonstrated a persistent 
increase of ROM and decrease in spasticity after rESWT, 
returning slowly back to baseline values five weeks after 
the last rESWT. This implies that any gain in ROM and 
spasticity can be attributed to rESWT, not the conventional 
rehabilitation programs. Since our follow up period was six 
weeks after the last rESWT, long term follow up studies are 
needed to precisely assess effects, especially safety aspects. 
In addition, a function scale for shoulder assessment 
should be pursued in future studies. We chose to focus on 
spasticity as an outcome measure to gauge the effectiveness 
of rESWT rather than functional measurements. The 
optimal number of treatments and treatment intervals has 
yet to be determined. Although a randomized controlled 
study is needed to conclude the effectiveness of rESWT for 
shoulder spasticity, we think this pilot study is important 
and has value for upcoming controlled studies. Future 
studies should focus on: (1) the effectiveness of rESWT 
versus focused ESWT; (2) the effectiveness of ESWT 
on the subscapularis and/or pectoralis major; (3) the 
effectiveness of ESWT versus botulinum toxin; and (4) the 
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most effective ESWT protocol.
In conclusion, this study demonstrated that rESWT 
can reduce spasticity in addition to decreasing pain and 
limitations in ROM of the shoulder. The results obtained 
regarding the safety and short-term efficacies of this 
treatment for the spastic subscapularis suggest that rESWT 
can provide an effective and safe procedure for spasticity 
treatment. The reduction in spasticity and pain and 
improvement of ROM continued four weeks after the last 
treatment, and then the beneficial effects of the treatment 
decreased afterward. Further studies are needed to support 
these results and to understand the mechanism of ESWT 
for the treatment of spasticity.
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